LynxDx is a cancer diagnostics company with the mission to improve patient care by bringing novel diagnostic assays to the market. We are leveraging cutting edge genomic technologies and have performed robust validation studies to ensure that we are providing patients and physicians with trustworthy and clinically impactful tools for patient care.
LynxDx, Inc. is a privately held pre-revenue diagnostic company headquartered in Ann Arbor, Michigan, with research facilities just a few miles away from the University of Michigan Health System. LynxDx currently is focused on commercializing diagnostic tools, including a diagnostic qPCR assay for COVID-19 and a urine assay to aid in diagnosis of prostate cancer (MyProstateScore). We currently operate a CLIA-licensed high-complexity molecular diagnostics laboratory that serves to commercially provide our diagnostic assays.